A therapeutic trial in migraine with parachlorophenylalanine, a specific serotonin depletor. 1970

F Sicuteri, and B Anselmi, and M Fanciullacci

UI MeSH Term Description Entries
D008881 Migraine Disorders A class of disabling primary headache disorders, characterized by recurrent unilateral pulsatile headaches. The two major subtypes are common migraine (without aura) and classic migraine (with aura or neurological symptoms). (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1) Acute Confusional Migraine,Headache, Migraine,Status Migrainosus,Abdominal Migraine,Cervical Migraine Syndrome,Hemicrania Migraine,Migraine,Migraine Headache,Migraine Variant,Sick Headache,Abdominal Migraines,Acute Confusional Migraines,Cervical Migraine Syndromes,Disorder, Migraine,Disorders, Migraine,Headache, Sick,Headaches, Migraine,Headaches, Sick,Hemicrania Migraines,Migraine Disorder,Migraine Headaches,Migraine Syndrome, Cervical,Migraine Syndromes, Cervical,Migraine Variants,Migraine, Abdominal,Migraine, Acute Confusional,Migraine, Hemicrania,Migraines,Migraines, Abdominal,Migraines, Acute Confusional,Migraines, Hemicrania,Sick Headaches,Variant, Migraine,Variants, Migraine
D010649 Phenylalanine An essential aromatic amino acid that is a precursor of MELANIN; DOPAMINE; noradrenalin (NOREPINEPHRINE), and THYROXINE. Endorphenyl,L-Phenylalanine,Phenylalanine, L-Isomer,L-Isomer Phenylalanine,Phenylalanine, L Isomer
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D002713 Chlorine An element with atomic symbol Cl, atomic number 17, and atomic weight 35, and member of the halogen family. Chlorine Gas,Chlorine-35,Cl2 Gas,Chlorine 35,Gas, Chlorine,Gas, Cl2
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006897 Hydroxyindoleacetic Acid 5-HIAA,5-Hydroxy-3-Indoleacetic Acid,5-Hydroxyindolamine Acetic Acid,5 Hydroxy 3 Indoleacetic Acid,5 Hydroxyindolamine Acetic Acid,Acetic Acid, 5-Hydroxyindolamine,Acid, 5-Hydroxy-3-Indoleacetic,Acid, 5-Hydroxyindolamine Acetic,Acid, Hydroxyindoleacetic

Related Publications

F Sicuteri, and B Anselmi, and M Fanciullacci
July 1978, Cell and tissue research,
F Sicuteri, and B Anselmi, and M Fanciullacci
December 1966, The Journal of pharmacology and experimental therapeutics,
F Sicuteri, and B Anselmi, and M Fanciullacci
January 1990, Acta physiologica Hungarica,
F Sicuteri, and B Anselmi, and M Fanciullacci
April 1973, The British journal of psychiatry : the journal of mental science,
F Sicuteri, and B Anselmi, and M Fanciullacci
January 1980, The Journal of pharmacology and experimental therapeutics,
F Sicuteri, and B Anselmi, and M Fanciullacci
May 1968, Diseases of the nervous system,
F Sicuteri, and B Anselmi, and M Fanciullacci
January 1970, Transactions of the American Neurological Association,
F Sicuteri, and B Anselmi, and M Fanciullacci
January 1970, Psychopharmacologia,
F Sicuteri, and B Anselmi, and M Fanciullacci
January 1968, Advances in pharmacology,
F Sicuteri, and B Anselmi, and M Fanciullacci
February 1990, Behavioral neuroscience,
Copied contents to your clipboard!